Intellia Therapeutics, Inc. NGM · NTLA

Gene Editing Therapeutics: Transforming Biopharmaceuticals with 12.5% CAGR Growth Forecast

GlobeNewswire Inc. · 19d ago

Global CRISPR-Based Drug Development Platforms Market to Reach USD 0.79 Billion by 2031: Precision Medicine and Gene Therapy Drive Growth

GlobeNewswire Inc. · 19d ago

Wall Street Expects This Growth Stock That's Already Climbed 70% to Almost Double -- And Here's Why.

The Motley Fool · 28d ago

Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?

The Motley Fool · 32d ago

This Stock Is Up 58% This Year. Is It too Late to Buy?

The Motley Fool · 35d ago

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

GlobeNewswire Inc. · 39d ago

1 Sector Warren Buffett and Greg Abel Are Largely Ignoring -- and Why Investors Shouldn't

The Motley Fool · 49d ago

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

The Motley Fool · 77d ago

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

GlobeNewswire Inc. · 84d ago

S&P 500 Holds Near Highs Despite Oil Shock and Weak Breadth Data

Investing.com · 86d ago

3 Biotech Stocks That Could Benefit from the Patent Cliff

Investing.com · 86d ago

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire Inc. · 110d ago

This Cathie Wood Stock Is Already Up 41% This Year, But Is It a Buy?

The Motley Fool · 165d ago

Genome Editing Market Forecast to Reach $23.6 Billion by 2031 Registering 16.6% CAGR: Insights Into Technology and Investment Trends

GlobeNewswire Inc. · 181d ago

Gene Editing Market Size to Surpass USD 42.13 Billion by 2034

GlobeNewswire Inc. · 260d ago

Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130%

The Motley Fool · 262d ago

CRISPR Therapies Clinical Trial Pipeline Shows Potential with Active Contributions from 25+ Key Companies | DelveInsight

GlobeNewswire Inc. · 293d ago

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Benzinga · 300d ago

Russell 2000 Hits All-Time Highs: 8 Stocks Power Small-Cap Comeback

Benzinga · 307d ago

Intellia Therapeutics Shares Are Ripping Higher: Here's Why

Benzinga · 307d ago

Gene Editing Market to Surpass USD 15.46 Billion by 2032, Fueled by Breakthroughs in CRISPR Technology and Precision Medicine – SNS Insider

GlobeNewswire Inc. · 323d ago

INTELLIA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Intellia Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

GlobeNewswire Inc. · 355d ago

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

GlobeNewswire Inc. · 402d ago

Analysts Think These Stocks Could More Than Double in Value

Investing.com · 425d ago

Angioedema Clinical Trial Pipeline Analysis Demonstrates 15+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight

GlobeNewswire Inc. · 442d ago